Literature DB >> 31925705

A pilot study on the Vanderbilt head and neck symptom survey Italian version (VHNSS-IT) to test its feasibility and utility in routine clinical practice.

Marta Maddalo1,2, Michela Buglione3, Nadia Pasinetti4, Luca Triggiani3, Ludovica Pegurri3, Alessandro Magli5, Stefano M Magrini3, Barbara A Murphy6.   

Abstract

PURPOSE: Patient-reported outcome measures can be useful to assess symptoms in head and neck cancer (HNC) patients treated with radio-chemotherapy. This is a pilot study on the VHNSS-IT (the Italian version of the Vanderbilt head and neck symptom survey) performed to assess both the feasibility and utility of its administration in clinical practice.
METHODS: The outcomes analyzed were feasibility to recruit patients, feasibility to complete the questionnaire, feasibility to review the questionnaire, utility perceived by clinicians, distribution of patient's answers reflecting symptom's intensity.
RESULTS: Among the 38 patients enrolled, 37 completed the VHNSS-IT (refusal rate 2.6%). Median time of completion was 6'57″. Time of completion was influenced by age (p = 0.002), grade of education (p = 0.023) and employment status (p = 0.004). Time after the start of the radiotherapy course (< 6 months vs. > 6 months) and surgery (yes vs. no) influenced symptoms' intensity. Median time for review was 2'15″. Time burden was perceived to be acceptable for all clinicians; they all also found the questionnaire easy to use. Rates of global perceived utility and future intention to use the questionnaire were 100%.
CONCLUSIONS: The VHNSS-IT has demonstrated to be a useful measurement of symptoms' burden for patients with HNC. The survey can be easily completed during the clinic routine without interfering with doctors' visits schedule, and it can help healthcare providers to identify symptoms that require referral, education or intervention.

Entities:  

Keywords:  Head and neck cancer; Patient-reported outcome measure; Symptoms screening

Year:  2020        PMID: 31925705     DOI: 10.1007/s11547-019-01125-6

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  15 in total

1.  Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health.

Authors:  Emily Cooperstein; Jill Gilbert; Joel B Epstein; Mary S Dietrich; Stewart M Bond; Sheila H Ridner; Nancy Wells; Anthony Cmelak; Barbara A Murphy
Journal:  Head Neck       Date:  2011-08-24       Impact factor: 3.147

2.  Gastrostomy dependence in head and neck carcinoma patient receiving post-operative therapy.

Authors:  Takeshi Shinozaki; Ryuichi Hayashi; Masakazu Miyazaki; Toshifumi Tomioka; Sadamoto Zenda; Makoto Tahara; Tetsuo Akimoto
Journal:  Jpn J Clin Oncol       Date:  2014-08-21       Impact factor: 3.019

3.  Functional evaluation of the spinal accessory nerve after neck dissection.

Authors:  B Leipzig; J Y Suen; J L English; J Barnes; M Hooper
Journal:  Am J Surg       Date:  1983-10       Impact factor: 2.565

4.  Shoulder disability after different selective neck dissections (levels II-IV versus levels II-V): a comparative study.

Authors:  Johnny Cappiello; Cesare Piazza; Marco Giudice; Giovanni De Maria; Piero Nicolai
Journal:  Laryngoscope       Date:  2005-02       Impact factor: 3.325

5.  Mouth opening and trismus in patients undergoing curative treatment for head and neck cancer.

Authors:  F Steiner; J Evans; R Marsh; P Rigby; S James; K Sutherland; R Wickens; N Nedev; B Kelly; S T Tan
Journal:  Int J Oral Maxillofac Surg       Date:  2015-01-07       Impact factor: 2.789

6.  A longitudinal study of pain variability and its correlates in ambulatory patients with advanced stage cancer.

Authors:  Junya Zhu; Roger B Davis; Sherri O Stuver; Donna L Berry; Susan Block; Jane C Weeks; Saul N Weingart
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

7.  Head and neck cancer in primary care: presenting symptoms and the effect of delayed diagnosis of cancer cases.

Authors:  Olli-Pekka Alho; Heikki Teppo; Pekka Mäntyselkä; Saara Kantola
Journal:  CMAJ       Date:  2006-03-14       Impact factor: 8.262

8.  Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy.

Authors:  Joel B Epstein; Diana J Wilkie; Dena J Fischer; Young-Ok Kim; Dana Villines
Journal:  Head Neck Oncol       Date:  2009-07-14

9.  Maximum mouth opening and trismus in 143 patients treated for oral cancer: a 1-year prospective study.

Authors:  Jan-Willem G H Wetzels; Matthias A W Merkx; Anton F J de Haan; Ron Koole; Caroline M Speksnijder
Journal:  Head Neck       Date:  2014-01-30       Impact factor: 3.147

Review 10.  Systemic and global toxicities of head and neck treatment.

Authors:  Barbara A Murphy; Jill Gilbert; Sheila H Ridner
Journal:  Expert Rev Anticancer Ther       Date:  2007-07       Impact factor: 4.512

View more
  3 in total

1.  Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Alessandro Ottaiano; Guglielmo Nasti; Michelearcangelo La Porta; Ginevra Danti; Salvatore Cappabianca; Carmen Cutolo; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Med       Date:  2021-11-29       Impact factor: 3.469

Review 2.  Role of Texture Analysis in Oropharyngeal Carcinoma: A Systematic Review of the Literature.

Authors:  Eleonora Bicci; Cosimo Nardi; Leonardo Calamandrei; Michele Pietragalla; Edoardo Cavigli; Francesco Mungai; Luigi Bonasera; Vittorio Miele
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

3.  Translation and cross-cultural adaption of the Chinese version of the Vanderbilt Head and Neck Symptom Survey version 2.0: a tool for oral symptom assessment in head and neck cancer patients.

Authors:  Min Jin; Li Sun; Rui Meng; Wenjing Wang; Rui Sun; Jing Huang; You Qin; Bian Wu; Qian Ding; Gang Peng; Tao Zhang; Kunyu Yang
Journal:  Health Qual Life Outcomes       Date:  2021-01-21       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.